Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 mars 2011 11h14 HE | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners to Present at the ROTH 23rd Annual OC Growth Stock Conference

CORAL GABLES, Fla., March 9, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that Patrick J. McEnany, Catalyst's Chief Executive Officer, will be making a...
08 mars 2011 09h04 HE | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners, Inc. Announces Public Offering of Common Shares

CORAL GABLES, Fla., March 8, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it has agreed to sell 2,259,943 shares of its common stock at a price of...
25 janv. 2011 08h03 HE | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Promotes Steven R. Miller, Ph.D. to Chief Operating Officer

CORAL GABLES, Fla., Jan. 25, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that Steven R. Miller, Ph.D., Catalyst's Chief Scientific Officer, has been...
04 janv. 2011 08h03 HE | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners to Present at the Biotech Showcase(TM) 2011 Conference

CORAL GABLES, Fla., Jan. 4, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that Patrick J. McEnany, Catalyst's Chief Executive Officer, will be making a...
09 déc. 2010 08h03 HE | Source: Catalyst Pharmaceuticals, Inc.

Canadian Intellectual Property Office Grants Broad Patent for the Use of Vigabatrin/CPP-109 for the Prevention of Addiction in Pain Management

CORAL GABLES, Fla., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that the Canadian Intellectual Property Office (CIPO) granted to Brookhaven...
18 nov. 2010 08h03 HE | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Initiates a Registration-Directed U.S. Phase II(b) Clinical Trial in Collaboration With The National Institute on Drug Abuse and Veteran's Administration Cooperative Studies Program

CORAL GABLES, Fla., Nov. 18, 2010 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that in collaboration with the National Institute on Drug Abuse (NIDA) and...
16 nov. 2010 08h03 HE | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Announces Third Quarter 2010 Financial and Operational Results

CORAL GABLES, Fla., Nov. 16, 2010 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial and operational results for the third quarter and nine months...
15 nov. 2010 08h03 HE | Source: Catalyst Pharmaceuticals, Inc.

Dr. Richard B. Silverman Joins Catalyst Pharmaceutical Partners' Scientific Advisory Board

Dr. Silverman is the Inventor of Pfizer's $3 Billion Lyrica® and Catalyst's CPP-115 CORAL GABLES, Fla., Nov. 15, 2010 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX)...
01 nov. 2010 14h30 HE | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Awarded $488,958 in Grants for Its CPP-109 and CPP-115 Projects Under the Section 48D Therapeutic Discovery Program

CORAL GABLES, Fla., Nov. 1, 2010 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that it has been awarded a total of $488,958 in grants for two qualifying...
01 nov. 2010 06h30 HE | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Reports Positive Non-Clinical Safety and Efficacy Results for CPP-115

Significant Improvement in Retinal Safety vs. Vigabatrin Results Support Completing IND Enabling Studies Catalyst to Hold Conference Call at 8:30 am ET Today to Discuss Results CORAL GABLES,...

Page précédente